Generic drug makers Teva Pharmaceutical Industries and Dr Reddy’s Laboratories have announced the commercial launch of olanzapine tablets, a generic version of Eli Lilly antipsychotic Zyprexa.

Teva will introduce tablets in 2.5mg, 5mg, 7.5mg, 10mg, 15mg doses, while Dr Reddy’s will introduce a 20mg tablet. Both companies have been granted a 180-day period of marketing exclusivity in the US for their respective tablets.

Dr Reddy’s is supplying the 20mg version of the product as part of a commercialisation, manufacture and supply agreement agreed in April 2011.

In addition, Dr Reddy’s will launch its 2.5mg, 5mg, 7.5mg, 10mg, 15mg and 20mg olanzapine tablets upon expiration of the 180-day exclusivity period.

Annual sales of Zyprexa in the US stood at approximately $3.2bn as of September 2011.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.